The Twice-Rejected Oncolytic Virus That Could Rewrite Melanoma Treatment

The FDA's PDUFA target action date for Replimune's RP1 was August 2, 2026. The agency has twice rejected the drug. A third decision is now imminent.

What makes this moment extraordinary is not just the regulatory drama — it's the science. RP1 (vusolimogene oderparepvec) is a genetically engineered herpes simplex virus designed to do something that sounded like science fiction a decade ago: infect and destroy melanoma cells from the inside, then trigger the immune system to hunt down tumors the virus never touched.

What RP1 Actually Does

RP1 is built on a proprietary strain of HSV-1, the virus that causes cold sores. Replimune's engineers armed it with two genetic payloads: a fusogenic protein called GALV-GP R- that makes the virus burst tumor cells more aggressively, and GM-CSF, an immune-stimulating cytokine that recruits dendritic cells to the site of tumor destruction. The result is a one-two punch — direct viral killing of injected tumors followed by a systemic immune response that can reach distant, uninjected lesions.

This mechanism distinguishes RP1 from Amgen's Imlygic (talimogene laherparepvec, or T-VEC), the only FDA-approved oncolytic virus in melanoma. T-VEC was approved in 2015 for early-stage, injectable cutaneous lesions. It has never demonstrated meaningful activity in the anti-PD-1-refractory, visceral disease setting that RP1 targets — patients whose melanoma has spread to lungs, liver, and other organs after failing checkpoint inhibitor therapy.

That population is the crux of the story. There is currently no FDA-approved therapy for patients with advanced melanoma whose disease has progressed after anti-PD-1 treatment. The only approved option in this space is Iovance's Amtagvi (lifileucel), a tumor-infiltrating lymphocyte therapy that requires extracting immune cells from a patient's resected tumor, expanding them ex vivo, and reinfusing them — a logistically complex, high-cost process available at a limited number of centers.

The IGNYTE Trial: Compelling Data, Flawed Design

The evidence supporting RP1 comes from the IGNYTE trial (NCT03767348), a Phase 1/2 single-arm study that enrolled 140 patients with advanced melanoma who had confirmed disease progression on anti-PD-1 therapy for at least 8 weeks. The results, published in the Journal of Clinical Oncology, were striking:

By independent central review, the confirmed objective response rate was 33.6% using modified RECIST v1.1 criteria (32.9% by standard RECIST), including a 15.0% complete response rate. The median duration of response exceeded 24 months. A 3-year landmark overall survival analysis presented at ASCO 2026 showed a median OS of 32.9 months — with median OS not reached among responders compared to 18.5 months among non-responders. One-year, two-year, and three-year overall survival rates were 75.3%, 61.5%, and 47.8%, respectively.

For a population with no approved treatment options, those numbers are extraordinary. But the FDA's reviewing scientists were not satisfied — and their concerns were methodological, not clinical.

Two Rejections and a Regulatory Reversal

The FDA issued its first Complete Response Letter (CRL) on July 21, 2025, finding that IGNYTE was "not an adequate and well-controlled clinical investigation capable of providing substantial evidence of effectiveness." The agency cited heterogeneity in the enrolled patient population and unresolved questions about the trial's single-arm design. No safety concerns were raised.

Replimune resubmitted in October 2025. The FDA issued a second CRL on April 10, 2026, again concluding that IGNYTE could not be considered a well-controlled trial. The core problem: without a randomized comparator arm, the agency could not determine whether observed responses were attributable to RP1 or to nivolumab rechallenge — since RP1 is administered in combination with Bristol Myers Squibb's Opdivo.

What happened next is where the story takes a political turn. Following the departure of FDA Commissioner Robert Califf and the installation of Marty Makary as the agency's new leader, Replimune reportedly received encouragement to resubmit a third time. According to reporting from CNBC, the White House intervened to facilitate the resubmission process. In June 2026, the FDA accepted the third BLA resubmission as a complete Class 1 response, setting the August 2, 2026 PDUFA date and scheduling the July 30 advisory committee meeting.

The Advisory Committee: Science vs. Statistics

The July 30 meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) was a collision between clinical urgency and statistical rigor. The FDA's own briefing documents were scathing, arguing that IGNYTE's single-arm design made it impossible to isolate RP1's contribution from nivolumab rechallenge, and that the survival analysis comparing responders to non-responders was "not interpretable" due to immortal time bias.

The committee wasn't swayed. By a 10-3 vote, panelists concluded that the efficacy results from IGNYTE were "evaluable and clinically meaningful." The majority argument was straightforward: in a patient population with no approved options, a 33% response rate with 15% complete responses and durable survival is meaningful — even from a single-arm trial — especially when responses were observed in non-injected lesions including visceral disease. The ongoing Phase 3 IGNYTE-3 confirmatory trial, they noted, would provide definitive answers.

"In my mind, this should be a therapy that's available to patients in the short term until the Phase 3 trial reads out," said Hussein Tawbi, a melanoma specialist at MD Anderson Cancer Center, who voted in favor.

The dissenters focused on the evidence gap. "I just don't even understand the data. I don't know what the response rate is. I don't know what to compare it to. We know that the chance of this being wrong, I think, is high," said Paul Chapman, chief medical research officer at Weill-Cornell's Meyer Cancer Center, who voted against.

Roughly 30 patients and advocates spoke during the public hearing, describing how RP1 had benefited them or their loved ones.

What an Approval Would Mean for Oncolytic Viruses

If the FDA approves RP1, it would mark a turning point for oncolytic virus therapy — a field that has been stuck in neutral since T-VEC's approval a decade ago. T-VEC demonstrated proof of concept but failed to meaningfully change practice because its activity was limited to injectable cutaneous lesions and it never improved overall survival in a randomized trial.

RP1's value proposition is different. It targets a harder, sicker population. It claims systemic activity — responses in visceral, non-injected lesions. And it does so in combination with a checkpoint inhibitor, potentially enhancing the immune activation that oncolytic viruses are designed to trigger. An approval would validate the oncolytic virus platform class and open a regulatory pathway for next-generation candidates.

The commercial implications are meaningful but not astronomical. The addressable population — anti-PD-1-refractory advanced melanoma — is relatively small. But the platform's applicability extends well beyond melanoma. Replimune is developing RP2, a next-generation oncolytic virus, and exploring combinations across solid tumors. An approval here de-risks the entire RPx platform.

What a Third Rejection Would Mean

If the FDA rejects RP1 for a third time, the consequences would be severe — both for Replimune and for the broader oncolytic virus field. Replimune would have to wait for Phase 3 IGNYTE-3 results, expected in late 2027, before resubmitting. The company posted a $313.9 million net loss for fiscal year 2026 and is burning cash rapidly; a third rejection would raise serious questions about its ability to survive to Phase 3 readout.

Beyond Replimune, a third rejection would send a chill through the oncolytic virus sector. Companies developing similar platforms — from DNAtrix's DNX-2401 to CG Oncology's oncolytic adenovirus programs — would face even higher regulatory bars. The message would be clear: the FDA considers single-arm trials insufficient for oncolytic virus approval, regardless of response rates or unmet need, and the path to market requires randomized Phase 3 data.

The Bigger Question: How Should the FDA Evaluate Single-Arm Trials?

The RP1 saga is really a debate about accelerated approval and the evidentiary standard for single-arm trials in oncology. The FDA's position is consistent with a broader trend under both the Califf and Makary administrations: demanding more rigorous evidence before approval, even under the accelerated pathway.

But the CTGTAC vote suggests that at least some experts believe the pendulum has swung too far. When patients are dying, when no approved therapy exists, and when a drug demonstrates a 33% response rate with durable complete responses in visceral disease — is a randomized controlled trial really the only acceptable evidence? Or is there room for judgment, particularly when a confirmatory Phase 3 trial is already underway?

The FDA's decision on RP1 — expected imminently — will answer that question. And the answer will shape how every oncolytic virus, every gene therapy, and every novel immunotherapy platform approaches the FDA for years to come.

---

Rich Washburn covers oncology, gene therapy, and regulatory science for The Daily Biologics.